KYSA-6: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Patients With Generalized Myasthenia Gravis

חו"ל (דורש נסיעה)מגייס משתתפיםPHASE2, PHASE3

מצבים רפואיים

Myasthenia Gravis · Generalized Myasthenia Gravis

סיכום בשפה פשוטהבעזרת בינה מלאכותית

הסיכום נכתב על־ידי מודל שפה והוא ניסיוני. המידע עלול להיות חלקי או שגוי ואינו תחליף לייעוץ רפואי.

מיקומים
  • Ronald Reagan UCLA Medical Center, Los Angeles, California, United States

  • University of California, Irvine, Orange, California, United States

  • Stanford University Medical Center, Palo Alto, California, United States

  • University of Miami, Miami, Florida, United States

  • Indiana University Health, Indianapolis, Indiana, United States

  • University of Missouri, Columbia, Missouri, United States

  • Oregon Health & Science University, Portland, Oregon, United States

    Contact: Study coordinator (Study Coordinatory)
  • Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States

  • Houston Methodist Hospital, Houston, Texas, United States

  • Intermountain Medical Center, Murray, Utah, United States

  • Westmead Institute for Medical Research, Westmead, Australia

  • Hospital Israelita Albert Einstein, São Paulo, Brazil

  • Charite- Universitätsklinikum Berlin, Berlin, Germany

  • Universitätsklinikum der Ruhr-Universität Bochum, Bochum, Germany

  • Universitätsklinikum Hamburg-Eppendorf, Hamburg, Germany

  • Medizinische Hochscule Hannover, Hanover, Germany

  • Friedrich-Schiller-Universität Jena, Jena, Germany

  • Universitätsklinik Magdeburg, Magdeburg, Germany

  • Technical University Munich, Klinikum Rechts der Isar, Munich, Germany

  • King's Faisal Specialist Hospital and Research Center, Riyadh, Kindom of Saudi Arabia, Saudi Arabia

  • Cambridge University Hospital, Addenbrooke's Hospital, Cambridge, United Kingdom

  • King's College Hospital, London, United Kingdom

מובילי המחקר
  • MD

    Study Director

    Kyverna Therapeutics, Inc.